Investors

Bioasis Technologies, Inc. is a science-driven company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Our goal is to generate shareholder value by developing and commercializing our proprietary brain delivery technology, xB3, to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose.

BTI.V
loading
loading
loading
Today's Open:
loading
Previous Close:
loading
High:
loading
Low:
loading
Volume:
loading

All Public Filings (Canada)

Most Recent Financial Reports (US)

Corporate Presentation

Investor News and Events

  • Dec. 13, 2018 Bioasis to Present at Investor & Industry Conferences in January 2019

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that members of management will present at the following investor… Read more »

  • Nov. 26, 2018 Bioasis Announces Voting Results for 2018 Annual and Special Meeting

    GUILFORD, Conn.–(Business Wire)–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the voting results from its Annual & Special… Read more »

  • Nov. 20, 2018 Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

    xB 3 -001 demonstrated lymphatic system penetration and more selective tissue distribution with xB 3 -001 than trastuzumab alone The Company has filed patent applications based on these observations and those data may have broader applicability An updated version of the corporate presentation is available for review at www.bioasis.us/investors

All Events and Presentations